Rating Change
Raymond James analysts initiated coverage on Xilio Therapeutics, Inc. (NASDAQ:XLO) with a rating of Outperform on October 21, 2026.
new coverageNASDAQ:XLO
Raymond James Initiates Coverage on Xilio Therapeutics, Inc. (XLO) with Outperform
Raymond James analysts initiated coverage on Xilio Therapeutics, Inc. (NASDAQ:XLO) with a rating of Outperform on October 21, 2026.
At publication ·
What changed
Xilio Therapeutics, Inc. (NASDAQ:XLO) · new coverage
- Firm
- Raymond James
- Rating
- Outperform
- Price at event
- $8.75
- Market capitalization
- $37.6M
At a glance
Key takeaways
- Raymond James initiated coverage of Xilio Therapeutics (XLO) with an Outperform rating on October 21, 2026.
- XLO trades at $8.75 with a $37.6M market capitalization and has declined 17.9% over the past 52 weeks.
Market Context
Xilio Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $8.75 with a market capitalization of $37.6M. The stock has declined 17.9% over the past 52 weeks.
Analyst coverage from Raymond James provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Xilio Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Xilio Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 21, 2026 | Raymond James | Outperform | N/A |
| Aug 06, 2025 | Leerink Partners | Outperform | N/A |
| Nov 08, 2024 | Raymond James | Outperform | N/A |
| May 30, 2023 | Chardan Capital | Buy | N/A |
| May 11, 2023 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View XLO Stock Page
Frequently Asked Questions
What does the Outperform rating mean for XLO?
A rating of Outperform from Raymond James reflects the analyst's outlook on Xilio Therapeutics, Inc. (NASDAQ:XLO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the XLO forecast page.